Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
Retrieved on:
Wednesday, April 7, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Cancer treatments, Cancer, Companies, Acute myeloid leukemia, Daiichi Sankyo, Acute lymphoblastic leukemia, 7+3, Antibody-drug conjugates, Antineoplastic drugs, Orphan drugs, Camidanlumab tesirine, Antibody-drug conjugate, the Study, Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, MLL, NPM1 and Menin, DS-1594, Daiichi Sankyo
Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo) today announced the first patient has been dosed in the first-in-human phase 1/2 study of DS-1594, a selective small-molecule menin inhibitor, in adults with relapsed/refractory acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
Key Points:
- Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo) today announced the first patient has been dosed in the first-in-human phase 1/2 study of DS-1594, a selective small-molecule menin inhibitor, in adults with relapsed/refractory acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
- The trial is being conducted by The University of Texas MD Anderson Cancer Center under an existing strategic research collaboration.
- Together with MD Anderson, we will evaluate DS-1594 as a potential therapeutic option for patients with AML or ALL who have exhausted standard treatments.
- DS-1594 is a potent and selective small molecule menin inhibitor in clinical development in the Alpha portfolio of Daiichi Sankyo.